Treatment and hematopoietic SCT in aplastic anemia

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 161-

  Passweg, J R ^a   Aljurf, M ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; DECISION MAKING; DONOR; EDITORIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIBLING; UNRELATED DONORS;

ANEMIA, APLASTIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84873459448     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.229     Document Type: Editorial

References (2)

1. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430-438
2. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P et al. and for the European Group for Blood and Marrow Transplantation (EBMT). The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012; 47: 906-923